SIREN : 331901413
BIOSYSTEMES is a French company founded 41 years ago, specialized in the sector Edition de logiciels applicatifs. Based in COUTERNON (21560), this company of category ETI shows in 2024 a revenue of 1.4 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 391 460 € | 1 206 508 € | 1 031 912 € | 993 823 € | 1 062 902 € | 1 049 069 € | 1 304 670 € | 1 356 847 € | 1 477 668 € |
| Net income | 351 316 € | 220 280 € | 118 044 € | 61 328 € | 55 732 € | 4 577 € | 131 491 € | 130 844 € | 188 028 € |
| EBITDA | 475 389 € | 288 519 € | 116 587 € | -3 751 € | 18 219 € | -41 139 € | 135 375 € | 131 830 € | 174 393 € |
| Net margin | 25.2% | 18.3% | 11.4% | 6.2% | 5.2% | 0.4% | 10.1% | 9.6% | 12.7% |
In 2024, BIOSYSTEMES achieves revenue of 1.4 M€. Activity remains stable over the period (CAGR: -0.7%). Vs 2023, growth of +15% (1.2 M€ -> 1.4 M€). After deducting consumption (0 €), gross margin stands at 1.4 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 475 k€, representing 34.2% of revenue. Positive scissor effect: EBITDA margin improves by +10.3 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 351 k€, i.e. 25.2% of revenue. This profit can be retained or distributed to shareholders.
1 391 460 €
1 391 460 €
475 389 €
469 231 €
351 316 €
34.1%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 36%. The balance between equity and debt is satisfactory. Cash flow represents 25.5% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
0.048%
36.193%
25.48%
0.0
15.7%
In 2024, the debt ratio of BIOSYSTEMES (0.05) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2024, the financial autonomy of BIOSYSTEMES (36.2%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of BIOSYSTEMES (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 469.60. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
469.6
0.0
In 2024, the liquidity ratio of BIOSYSTEMES (469.60) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of BIOSYSTEMES (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 45 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 40 days. The company must finance 5 days of gap between collections and payments. Overall, WCR represents 81 days of revenue, i.e. 312 k€ to permanently finance. Over 2016-2024, WCR increased by +222%, requiring additional financing.
311 729 €
45 j
40 j
0 j
81 j
Based on 103 transactions of similar company sales (all years), the value of BIOSYSTEMES is estimated at 419 979 € (range 153 415€ - 1 257 297€). With an EBITDA of 475 389€, the sector multiple of 1.0x is applied. The price/revenue ratio is 0.25x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 103 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare BIOSYSTEMES with other companies in the same sector:
Voir toutes les statistiques du secteur Edition de logiciels applicatifs
The revenue of BIOSYSTEMES in 2024 is 1.4 M€.
Yes, BIOSYSTEMES generated a net profit of 351 k€ in 2024.
The headquarters of BIOSYSTEMES is located in COUTERNON (21560), in the department Cote-d'Or.
The tax return of BIOSYSTEMES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
BIOSYSTEMES operates in the sector Edition de logiciels applicatifs (NAF code 58.29C). See the 'Sector positioning' section above to compare the company with its competitors.